Nephrocare Health Services
Nephrocare Health Services Share Price Chart
Nephrocare Health Services last traded at ₹616.95 (2026-10-13). Over the past month the stock moved -17.7%, three months the stock moved +1.6%. Its closing range over 52 weeks is ₹449.15 – ₹766.55, with the latest close 19.5% below the high.
Closing prices up to 2026-10-13.
About Nephrocare Health Services
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
Business Profile[1] Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Nephrocare Health Services reported sales of ₹282.00 crore (+23.7%) and net profit of ₹32.00 crore (+33.3%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 282.00 | 60.00 | 21.00 | 32.00 | 3.19 |
| Mar 2026 | 266.00 | 51.00 | 19.00 | 30.00 | 3.03 |
| Dec 2025 | 260.00 | 61.00 | 23.00 | 32.00 | 3.21 |
| Sep 2025 | 246.00 | 64.00 | 26.00 | -9.00 | -5.24 |
| Jun 2025 | 228.00 | 48.00 | 21.00 | 24.00 | 13.10 |
| Mar 2025 | 219.00 | 51.00 | 23.00 | 25.00 | 119.30 |
| Dec 2024 | 197.00 | 44.00 | 22.00 | 20.00 | 96.50 |
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales growth | +32.0% | +21.5% | +23.7% |
| Operating profit growth | +38.6% | +0.0% | +25.0% |
| Net profit growth | +60.0% | +20.0% | +33.3% |
| EPS growth | -96.7% | -97.5% | -75.6% |
| OPM % | 23.0% | 19.0% | 21.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Nephrocare Health Services reported sales of ₹999.00 crore (+32.1%) and net profit of ₹77.00 crore (+14.9%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 999.00 | 224.00 | 22.00 | 77.00 | 7.66 |
| Mar 2025 | 756.00 | 167.00 | 22.00 | 67.00 | 321.87 |
| Mar 2024 | 566.00 | 101.00 | 18.00 | 35.00 | 169.82 |
| Mar 2023 | 437.00 | 49.00 | 11.00 | -12.00 | -58.69 |
| Mar 2022 | 318.00 | 16.00 | 5.00 | -21.00 | -106.93 |
| Mar 2021 | 286.00 | 37.00 | 13.00 | 1.00 | 3.40 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales growth | +11.2% | +37.4% | +29.5% | +33.6% | +32.1% |
| Operating profit growth | -56.8% | +206.3% | +106.1% | +65.3% | +34.1% |
| Net profit growth | -2200.0% | – | – | +91.4% | +14.9% |
| EPS growth | -3245.0% | – | – | +89.5% | -97.6% |
| OPM % | 5.0% | 11.0% | 18.0% | 22.0% | 22.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
NEPHROPLUS is trading at ₹703.55, up 30.47% in 1 month and 59.78% YTD, positioned just 5.2% below its 52W high of ₹682.1 with strong technical momentum (Tech Score 73.3, RSI 55, bullish trend). Revenue has grown at a robust 32% CAGR (3-year), with FY2026 sales reaching ₹999 Cr and operating margins steady at 22%; however, profitability shows volatility (Q3 FY26 net loss of ₹9 Cr offset by Q4 recovery to ₹30 Cr net profit), and ROE remains modest at 6.9% despite ROCE improvement to 15%. Primary near-term risk is the very low delivery % of 1.4%, indicating speculative intraday trading rather than institutional conviction, coupled with elevated P/B of 9.37 which demands sustained earnings momentum to justify valuation.
- Strong revenue growth momentum (32% CAGR 3-year, FY26 sales ₹999 Cr) with consistent operating margins around 22% demonstrating operational leverage in dialysis services model.
- Exceptional balance sheet deleveraging: D/E fell from 0.66 (Mar 2024) to 0.07 (Mar 2026) while OCF surged to ₹233 Cr, providing ample capex headroom for bed expansion and geographic diversification.
- Robust technical setup and sector leadership: Tech Score 73.3 with bullish trend, RSI 55 (neutral-to-bullish), trading in top 93rd percentile of healthcare services sector with asset transfer partnerships expanding capacity pipeline.
- Acute profitability volatility and ROE weakness: Q3 FY26 swung to ₹9 Cr net loss despite ₹246 Cr sales and 26% OPM (likely one-time charges), and full-year ROE of 6.9% lags cost of capital, raising questions on capital efficiency and earnings sustainability beyond cyclical recovery.
- Speculative retail dominance and valuation cliff risk: Delivery % of 1.4% signals intraday/speculative trading with minimal institutional conviction; elevated P/B of 9.37 implies zero margin of safety—any earnings miss or macro healthcare spending slowdown could trigger sharp 20–30% retracement to ₹550–600 range.
AI-generated analysis for informational purposes only — not SEBI-registered investment advice.
See Full AI Analysis — Free FREE →Latest News
-
Nephrocare Health’s arm enters into Asset Transfer Agreement with Juan Nephro Dialysis Center
-
Nephrocare Health shines as its arm inks asset transfer pact with Amica Healthcare System Corporation
-
Nephrocare Health’s arm inks asset transfer pact with Amica Healthcare System Corporation
-
Nephrocare Health jumps as its arm inks asset transfer pact with Inocentes Dialysis Clinic
-
Nephrocare Health’s arm inks asset transfer pact with Inocentes Dialysis Clinic
-
Nephrocare Health Services Ltd Hits All-Time High at Rs.670.40
-
Nephrocare Health Services’ arm incorporates wholly-owned subsidiary in Kazakhstan
-
Nephrocare Health Services shines as its arm inks Asset Transfer pact with Orani
Frequently Asked Questions
What is Nephrocare Health Services's current stock price?
Nephrocare Health Services shares were last quoted at ₹616.95 (+0.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Nephrocare Health Services?
Nephrocare Health Services has a price-to-earnings (P/E) ratio of 82.15 and a price-to-book (P/B) ratio of 6.07. The industry P/E is 101.02.
What is the 52-week high and low of Nephrocare Health Services?
The 52-week high of Nephrocare Health Services is ₹781.00 and the 52-week low is ₹445.00.
What is the market cap of Nephrocare Health Services?
The market capitalisation of Nephrocare Health Services is about ₹6,989.73 crore.
How did Nephrocare Health Services perform in its latest quarterly results?
In the latest quarter (Jun 2026), Nephrocare Health Services reported sales of ₹282.00 crore (+23.7%) and net profit of ₹32.00 crore (+33.3%), compared with the same quarter last year.
Is Nephrocare Health Services a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Nephrocare Health Services has a 3-year ROE of 10.00%, 3-year profit growth of 103.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Nephrocare Health Services?
Promoters hold about 63.85% of Nephrocare Health Services.
Which sector does Nephrocare Health Services belong to?
Nephrocare Health Services belongs to the Hospital & Healthcare Services sector.
Other Hospital & Healthcare Services stocks
- Apollo Hospitals Enterprises
- Max Healthcare Institute
- Manipal Health Enterprises
- Aster DM Quality Care
- Fortis Healthcare
- Global Health
- Narayana Hrudayalaya
- Krishna Institute of Medical Sciences
All Hospital & Healthcare Services stocks · Browse all stocks A–Z